for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion
Jeffrey Olgin



This study explores the hypothesis that wearable defibrillators can impact mortality by reducing sudden death during the first three months after a heart attack in persons with high risk for life-threatening arrhythmias.

Official Title

Vest Prevention of Early Sudden Death Trial: Prevention of Sudden Death After Myocardial Infarction Using a LifeVest Wearable Cardioverter-defibrillator (Formerly VEST/PREDICTS)


In patients with ventricular dysfunction immediately following myocardial infarction, sudden death may be responsible for up to 50% of total mortality. Wearable defibrillators may reduce sudden death by providing immediate detection and treatment of ventricular arrhythmias. This study is design to demonstrate a reduction in sudden death measured at three months following myocardial infarction among patients who have ventricular dysfunction.


Myocardial InfarctionVentricular DysfunctionSudden DeathVentricular TachycardiaVentricular Fibrillationmyocardial infarction, acutedeath, sudden, cardiacdeath, suddendeathdefibrillation, electriccardioversion, electricelectric countershockdefibrillators, externalInfarctionTachycardiaTachycardia, Ventricularwearable defibrillator


You can join if…

Open to people ages 18 years and up

  • Patients identified in the hospital or within 7 days after discharge with a diagnosis of an acute MI (STEMI or Non-STEMI)
  • LV ejection fraction ≤35% determined at the following time point:
  • If no PCI within the first 8 hours following the MI: ≥ 8 hours after MI
  • If acute PCI occurs within 8 hours of MI: ≥8 hours after PCI
  • If CABG is planned (before or within 7 days of discharge), wait to enroll and then use the most recent assessment at least 48 hours post CABG
  • Age ≥ 18 years

You CAN'T join if...

  • Existing ICD or indication for an ICD at the time of screening
  • Existing unipolar pacemakers/leads
  • Chronic renal failure requiring hemodialysis after hospital discharge
  • Chest circumference too small or too large for LifeVest garment*
  • Participants discharged to an institutional setting with an anticipated stay > 7 days
  • Pregnancy
  • Inability to consent
  • Any other condition or circumstance that in the judgment of the clinician makes the participant unsuitable for the study.


  • University of California, San Francisco
    San FranciscoCalifornia94143United States
  • Cardiovascular Consultants Heart Center
    FresnoCalifornia93720United States

Lead Scientist

  • Jeffrey Olgin
    CLINICAL INTERESTS: Dr. Olgin is a Cardiologist and a Cardiac Electrophysiologist. His main clinical interests include conduction disorders, arrhythmias, catheter ablation, implantable devices—pacemakers and defibrillators, atrial fibrillation, atrial flutter, ventricular tachycardia, sudden death and supraventricular tachycardia.


in progress, not accepting new patients
Start Date
Completion Date
University of California, San Francisco
Study Type
Last Updated